A novel approach incorporating sildenafil in the management of symptomatic neonates with Ebstein's anomaly.
The neonatal presentation of Ebstein's anomaly is a distinct cyanotic lesion for which little can be done other than to maintain ductal patency or perform palliative surgery if improvement does not occur. We report two cases in which sildenafil was introduced to assist previously failed attempts at weaning of prostaglandin.
Pham
Phat
P
Division of Pediatric Cardiology, Oregon Health & Science University, 707 SW Gaines Road, CDRC-P, Portland, OR 97239, USA.
Hoyer
Andrew
A
Shaughnessy
Robin
R
Law
Yuk M
YM
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D004305:Dose-Response Relationship, Drug; D004437:Ebstein Anomaly / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004452:Echocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011687:Purines; D013902:Radiography, Thoracic; D012720:Severity of Illness Index; D000068677:Sildenafil Citrate; D013450:Sulfones; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases